FDA Cleared Breakthrough Technology
for Migraine Pain Reduction
How to order
Migraine Pain Prevention now available without a prescription
Migraine is the #1 disability in adults under 50 years of age. Other than the specific headache pain symptoms that the migraine suffer describes, there are no objective abnormalites in the migraine patient, except for one particular ability: on average, migraine sufferers can clench their jaw with twice the force as asymptomatic controls.
While it was first thought nocturnal jaw clenching was in response to their pain, it was found that chronic headache sufferers clench their jaw during sleep with 14x the intensity as symptomatic controls.
For the chronic migraine and headache sufferer,
intense jaw clenching typically occurs just before waking.
The MigraineGuard (and MigraineGuardPRO) is the first OTC anti-clenching technology cleared by the FDA for the reduction of medically diagnosed migraine pain.
The MigraineGuard (and MigraineGuardPRO) prevent the pathologic nocturnal clenching intensity that produces the nociceptive (negative) trigeminal input known to increase migraine activity. In doing so, the MigraineGuard is also the ideal oral device therapy to treat and prevent TMD and jaw disorders (while preventing bruxism entirely). In a recent presentation at the 2018 International Migraine Trust in London, the MigraineGuard clenching suppression technology was shown to be nearly twice as effective than the most commonly prescribed medications for migraine prevention and just recently published in the Boston Medical Journal of Neurology.
Waking with a headache becomes part of the sufferer's daily private existence
How traditional dental mouthpieces miss the mark
When a patient is diagnosed with "nocturnal parafunction", that is, jaw clenching and/or teeth grinding (together known as "bruxism"), a dental protective splint, or "nightguard", is prescribed. The splint has two objectives: to protect the teeth from the damage of grinding; and to provide a balanced biting surface, so as to stabilize the jaw joints during clenching. However, the one thing the splint cannot do is prevent the parafunctional activity. If fact, the presence of the splint can allow clenching intensity to increase beyond the already pathologic level.
Providing a perfected clenching surface allows for increased clenching intensity
MigraineGuard employs patented "anti-clenching"technology
The MigraineGuard provides for an anterior mid-line dome shape incorporated into an upper mouthpiece, which opposes a flat surface lower mouthpiece. This patented design prevents the posterior surfaces from touching (which is required to achieve pathologic clenching intensity).
While minimizing clenching intensity, the anterior dome also provides for a "balanced" bite (zero on one side and zero on the other), thereby maintaining stable jaw joints, while making grinding impossible.
In a recent placebo-controlled, blinded, cross-over study, the MigraineGuard design provided a profound improvement in Quality of Life for 89% of chronic migraine sufferers.